Potent antiplatelet activity of sesamol in an in vitro and in vivo model: Pivotal roles of cyclic AMP and p38 mitogen-activated protein kinase

Chao C. Chang, Wan-Jung Lu, Cheng-Wen Chiang, Thanasekaran Jayakumar, Eng T. Ong, George Hsiao, Tsorng H. Fong, Duen S. Chou, Joen R. Sheu

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Sesamol is a potent phenolic antioxidant which possesses antimutagenic, antihepatotoxic and antiaging properties. Platelet activation is relevant to a variety of acute thrombotic events and coronary heart diseases. There have been few studies on the effect of sesamol on platelets. Therefore, the aim of this study was to systematically examine the detailed mechanisms of sesamol in preventing platelet activation in vitro and in vivo. Sesamol (2.5-5 μM) exhibited more potent activity of inhibiting platelet aggregation stimulated by collagen than other agonists. Sesamol inhibited collagen-stimulated platelet activation accompanied by [Ca2+]i mobilization, thromboxane A2 (TxA2) formation, and phospholipase C (PLC)γ2, protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) phosphorylation in washed platelets. Sesamol markedly increased cAMP and cGMP levels, endothelial nitric oxide synthase (eNOS) expression and NO release, as well as vasodilator-stimulated phosphoprotein (VASP) phosphorylation. SQ22536, an inhibitor of adenylate cyclase, markedly reversed the sesamol-mediated inhibitory effects on platelet aggregation and p38 MAPK phosphorylation, and sesamol-mediated stimulatory effects on VASP and eNOS phosphorylation, and NO release. Sesamol also reduced hydroxyl radical (OH{filled circle}) formation in platelets. In an in vivo study, sesamol (5 mg/kg) significantly prolonged platelet plug formation in mice. The most important findings of this study demonstrate for the first time that sesamol possesses potent antiplatelet activity, which may involve activation of the cAMP-eNOS/NO-cGMP pathway, resulting in inhibition of the PLCγ2-PKC-p38 MAPK-TxA2 cascade, and, finally, inhibition of platelet aggregation. Sesamol treatment may represent a novel approach to lowering the risk of or improving function in thromboembolism-related disorders.

Original languageEnglish
Pages (from-to)1214-1221
Number of pages8
JournalJournal of Nutritional Biochemistry
Volume21
Issue number12
DOIs
Publication statusPublished - Dec 2010

Fingerprint

p38 Mitogen-Activated Protein Kinases
Cyclic AMP
Platelets
Phosphorylation
Nitric Oxide Synthase Type III
Platelet Activation
Blood Platelets
Chemical activation
Platelet Aggregation
Thromboxane A2
Agglomeration
Protein Kinase C
sesamol
In Vitro Techniques
Collagen
Thromboembolism
Type C Phospholipases
Mitogen-Activated Protein Kinases
Adenylyl Cyclases
Hydroxyl Radical

Keywords

  • Cyclic AMP
  • Nitric oxide
  • P38 MAPK
  • Platelet activation
  • PLCγ2
  • Sesamol

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Potent antiplatelet activity of sesamol in an in vitro and in vivo model : Pivotal roles of cyclic AMP and p38 mitogen-activated protein kinase. / Chang, Chao C.; Lu, Wan-Jung; Chiang, Cheng-Wen; Jayakumar, Thanasekaran; Ong, Eng T.; Hsiao, George; Fong, Tsorng H.; Chou, Duen S.; Sheu, Joen R.

In: Journal of Nutritional Biochemistry, Vol. 21, No. 12, 12.2010, p. 1214-1221.

Research output: Contribution to journalArticle

@article{eb672ebe9d9a437a9272e01c27dec600,
title = "Potent antiplatelet activity of sesamol in an in vitro and in vivo model: Pivotal roles of cyclic AMP and p38 mitogen-activated protein kinase",
abstract = "Sesamol is a potent phenolic antioxidant which possesses antimutagenic, antihepatotoxic and antiaging properties. Platelet activation is relevant to a variety of acute thrombotic events and coronary heart diseases. There have been few studies on the effect of sesamol on platelets. Therefore, the aim of this study was to systematically examine the detailed mechanisms of sesamol in preventing platelet activation in vitro and in vivo. Sesamol (2.5-5 μM) exhibited more potent activity of inhibiting platelet aggregation stimulated by collagen than other agonists. Sesamol inhibited collagen-stimulated platelet activation accompanied by [Ca2+]i mobilization, thromboxane A2 (TxA2) formation, and phospholipase C (PLC)γ2, protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) phosphorylation in washed platelets. Sesamol markedly increased cAMP and cGMP levels, endothelial nitric oxide synthase (eNOS) expression and NO release, as well as vasodilator-stimulated phosphoprotein (VASP) phosphorylation. SQ22536, an inhibitor of adenylate cyclase, markedly reversed the sesamol-mediated inhibitory effects on platelet aggregation and p38 MAPK phosphorylation, and sesamol-mediated stimulatory effects on VASP and eNOS phosphorylation, and NO release. Sesamol also reduced hydroxyl radical (OH{filled circle}) formation in platelets. In an in vivo study, sesamol (5 mg/kg) significantly prolonged platelet plug formation in mice. The most important findings of this study demonstrate for the first time that sesamol possesses potent antiplatelet activity, which may involve activation of the cAMP-eNOS/NO-cGMP pathway, resulting in inhibition of the PLCγ2-PKC-p38 MAPK-TxA2 cascade, and, finally, inhibition of platelet aggregation. Sesamol treatment may represent a novel approach to lowering the risk of or improving function in thromboembolism-related disorders.",
keywords = "Cyclic AMP, Nitric oxide, P38 MAPK, Platelet activation, PLCγ2, Sesamol",
author = "Chang, {Chao C.} and Wan-Jung Lu and Cheng-Wen Chiang and Thanasekaran Jayakumar and Ong, {Eng T.} and George Hsiao and Fong, {Tsorng H.} and Chou, {Duen S.} and Sheu, {Joen R.}",
year = "2010",
month = "12",
doi = "10.1016/j.jnutbio.2009.10.009",
language = "English",
volume = "21",
pages = "1214--1221",
journal = "Journal of Nutritional Biochemistry",
issn = "0955-2863",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Potent antiplatelet activity of sesamol in an in vitro and in vivo model

T2 - Pivotal roles of cyclic AMP and p38 mitogen-activated protein kinase

AU - Chang, Chao C.

AU - Lu, Wan-Jung

AU - Chiang, Cheng-Wen

AU - Jayakumar, Thanasekaran

AU - Ong, Eng T.

AU - Hsiao, George

AU - Fong, Tsorng H.

AU - Chou, Duen S.

AU - Sheu, Joen R.

PY - 2010/12

Y1 - 2010/12

N2 - Sesamol is a potent phenolic antioxidant which possesses antimutagenic, antihepatotoxic and antiaging properties. Platelet activation is relevant to a variety of acute thrombotic events and coronary heart diseases. There have been few studies on the effect of sesamol on platelets. Therefore, the aim of this study was to systematically examine the detailed mechanisms of sesamol in preventing platelet activation in vitro and in vivo. Sesamol (2.5-5 μM) exhibited more potent activity of inhibiting platelet aggregation stimulated by collagen than other agonists. Sesamol inhibited collagen-stimulated platelet activation accompanied by [Ca2+]i mobilization, thromboxane A2 (TxA2) formation, and phospholipase C (PLC)γ2, protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) phosphorylation in washed platelets. Sesamol markedly increased cAMP and cGMP levels, endothelial nitric oxide synthase (eNOS) expression and NO release, as well as vasodilator-stimulated phosphoprotein (VASP) phosphorylation. SQ22536, an inhibitor of adenylate cyclase, markedly reversed the sesamol-mediated inhibitory effects on platelet aggregation and p38 MAPK phosphorylation, and sesamol-mediated stimulatory effects on VASP and eNOS phosphorylation, and NO release. Sesamol also reduced hydroxyl radical (OH{filled circle}) formation in platelets. In an in vivo study, sesamol (5 mg/kg) significantly prolonged platelet plug formation in mice. The most important findings of this study demonstrate for the first time that sesamol possesses potent antiplatelet activity, which may involve activation of the cAMP-eNOS/NO-cGMP pathway, resulting in inhibition of the PLCγ2-PKC-p38 MAPK-TxA2 cascade, and, finally, inhibition of platelet aggregation. Sesamol treatment may represent a novel approach to lowering the risk of or improving function in thromboembolism-related disorders.

AB - Sesamol is a potent phenolic antioxidant which possesses antimutagenic, antihepatotoxic and antiaging properties. Platelet activation is relevant to a variety of acute thrombotic events and coronary heart diseases. There have been few studies on the effect of sesamol on platelets. Therefore, the aim of this study was to systematically examine the detailed mechanisms of sesamol in preventing platelet activation in vitro and in vivo. Sesamol (2.5-5 μM) exhibited more potent activity of inhibiting platelet aggregation stimulated by collagen than other agonists. Sesamol inhibited collagen-stimulated platelet activation accompanied by [Ca2+]i mobilization, thromboxane A2 (TxA2) formation, and phospholipase C (PLC)γ2, protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) phosphorylation in washed platelets. Sesamol markedly increased cAMP and cGMP levels, endothelial nitric oxide synthase (eNOS) expression and NO release, as well as vasodilator-stimulated phosphoprotein (VASP) phosphorylation. SQ22536, an inhibitor of adenylate cyclase, markedly reversed the sesamol-mediated inhibitory effects on platelet aggregation and p38 MAPK phosphorylation, and sesamol-mediated stimulatory effects on VASP and eNOS phosphorylation, and NO release. Sesamol also reduced hydroxyl radical (OH{filled circle}) formation in platelets. In an in vivo study, sesamol (5 mg/kg) significantly prolonged platelet plug formation in mice. The most important findings of this study demonstrate for the first time that sesamol possesses potent antiplatelet activity, which may involve activation of the cAMP-eNOS/NO-cGMP pathway, resulting in inhibition of the PLCγ2-PKC-p38 MAPK-TxA2 cascade, and, finally, inhibition of platelet aggregation. Sesamol treatment may represent a novel approach to lowering the risk of or improving function in thromboembolism-related disorders.

KW - Cyclic AMP

KW - Nitric oxide

KW - P38 MAPK

KW - Platelet activation

KW - PLCγ2

KW - Sesamol

UR - http://www.scopus.com/inward/record.url?scp=78249234191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78249234191&partnerID=8YFLogxK

U2 - 10.1016/j.jnutbio.2009.10.009

DO - 10.1016/j.jnutbio.2009.10.009

M3 - Article

C2 - 20015631

AN - SCOPUS:78249234191

VL - 21

SP - 1214

EP - 1221

JO - Journal of Nutritional Biochemistry

JF - Journal of Nutritional Biochemistry

SN - 0955-2863

IS - 12

ER -